Core Viewpoint - Novo Nordisk's oral GLP-1 weight loss drug, Wegovy, has exceeded market expectations with rapid prescription growth, outperforming its injectable version and competitors in the same category [4][6]. Group 1: Market Performance - In just two weeks post-launch, oral Wegovy achieved approximately 18,400 prescriptions, with some estimates nearing 20,000, compared to 1,600 for the injectable version and 7,300 for Eli Lilly's Zepbound during the same period [4]. - The strong performance of oral Wegovy is crucial for Novo Nordisk to regain its footing in the weight loss market, which has been challenged by Eli Lilly's competitive advantages [6]. Group 2: Product Attributes - Oral Wegovy received FDA approval in December 2025 as the first oral GLP-1 drug for obesity treatment, with a maximum daily dose of 25 mg and an indication for reducing cardiovascular risk, broadening its applicability [6]. - The pricing strategy for oral Wegovy is set at $149 per month for cash-paying patients, with a minimum of $25 for those with commercial insurance through the company's discount program, which is seen as a key factor for early adoption [6]. Group 3: Industry Implications - The rapid uptake of oral Wegovy signals strong market demand for oral GLP-1 weight loss drugs, potentially benefiting Eli Lilly's upcoming oral product, orforglipron [7]. - Analysts note that the competitive landscape is shifting from efficacy comparisons to factors like administration method, affordability, and long-term adherence, indicating a new phase in the weight loss drug market [8].